Research Manitoba End of Grant Report Instructions

The End of Grant Report is intended to elicit information about the activities and accomplishments of the research program/project supported by Research Manitoba. Specifically, it aims to

- Determine research discoveries and accomplishments (i.e. outputs and outcomes);
- Assess if original goals/objectives were achieved;
- Identify knowledge translation activities;
- Identify issues and lessons learned about the award/grant.

The information collected from the end of grant reports will be used to a) inform Research Manitoba's strategy and programs, and will be a vital component to justify and ensure long-term and sustainable funding; b) identify and track outputs and outcomes of supported research program/project; and c) communicate the value and benefits of research.

Names as well as other personal identifiers will be used ONLY by Research Manitoba staff for the purposes of following up or clarifying ambiguous information and will not be used in any report. Data, when reported, will be done in the aggregate. In order to communicate the successes of the research, Research Manitoba may use content from this report in donor and stakeholder communications, with permission from the award holder.

In this report, **Outputs** are defined as the tangible findings or the direct products or services of research activities or infrastructure. **Outcomes** are the changes, benefits, or other effects that happen as a result of the research or research infrastructure. Outputs and Outcomes are collectively referred to as **Impact**. **Please report only on outputs and outcomes supported by this Research Manitoba grant.**

When preparing the Report,

- The person filling it up should be the lead investigator or proponent or project coordinator/ manager;
- Ensure information is updated and, and where appropriate, consistent with information in the lead investigator's CCV;
- Provide specifics when answering, supported by quantitative data when available and appropriate;
- If more rows/space are needed for any question(s), please attach additional pages to this report;
- Depending on the nature of the supported project, some questions may not be applicable. Please use 'None' and 'Not applicable' only as appropriate;
- Research Manitoba may follow up about the outcomes and other impacts of completed projects/ programs. Please provide a person's name and contact details who can be contacted at least 3-5 years after completing this Report.

The End of Grant Report is due two months (unless otherwise specified) after being notified by Research Manitoba.

If you have any question or feedback on the form, please do not hesitate to contact us at (204) 942-1918 or at mailto: mailto:necole.sommersell@researchmb.ca or at info@researchmb.ca.

END OF GRANT REPORT

BACKGROUND

Last Name:	First Name:		Initial:
Street:	City:	Province:	Postal code:
Telephone:	Email:		·
2. Institution primarily affiliated with (Thi	s section refers to the primary institution	al affiliation of the lead investigator or	proponent)
Institution:			
Faculty:			
Department:			
3. Areas of research (This section refers to the	ne lead investigator or proponent)		
Areas of research (Enter at least 2):			
Condition or issue that is the research inte	rest :		
Research Pillar (only for health research):	Years as indepe	endent researcher in Manitoba:	
	<u> </u>		
4. Award/grant information (This section re	efers to the proposal submitted to Resear	rch Manitoba)	
Name of Research Manitoba award/grant:		,	
Amount:	Start date (MM/YYYY):	End date (MM/YYYY):	Duration (in years):
Program/project title:	·	·	
Program/project description:			
Goals of research program/project:			
Specific objectives:			
5. Please provide a name and contact info	ormation of a person who can be con	tacted 3-5 years after completing	this Report for follow up regardin
5. Please provide a name and contact info	•	, , ,	this Report for follow up regardin
•	•	, , ,	this Report for follow up regardin
· · · · · · · · · · · · · · · · · · ·	acts of the completed project/progr	, , ,	

PUBLICATIONS/COMMUNICATIONS

1. Please list publications that have been <u>supported</u> by this Research Manitoba award/grant. <u>Type</u> of publication can be journal article/review, book, book chapter, book reviews, dissertation, technical reports, working papers, manuals, online resources, clinical care guidelines, conference publications, abstracts, guides, monographs, policy briefing report, and others which should be specified. Status of publication can be published, in-press and under review.

Publication details	Туре	Status	

2. Please list all communication activities you have carried out to date. If no communication activities done to date, please provide an explanation.

Activity refers to talks, lectures, workshops, formal working group, expert panel, dialogue, meetings, discussions, keynote/invited speaker, poster presentations in a conference/symposium, paper presentations in a conference/symposium, press release, press conference, response to media, broadcast interview, print/text interviews (magazines, newsletters or online publications), informal talks, blogs, open day, visit to research institute, and others which should be specified. Purpose can include sharing of information, inform decision making, improve understanding etc. Location refers to the place where the activity was held e.g. Manitoba, USA, etc. Number of activities is the number of times the activity was carried out. Number reached is the estimated number of people reached by the activity. Year refers to year when activities were carried out.

Audience	Sector	Activity	Purpose	Location	# of activities	Number reached	Year
Research participants							
Patient Groups							
Academics/other							
researchers							
Professionals and							
practitioners/clinicians							
Policy/decision makers							
(specify if federal, provincial,							
municipal, institutional)							
Public/other audiences							

Media (specify if print, television, radio, social media)				
Schools and students (please indicate if the audience are high school or university students)				
Industry (specify such as biotechnology, pharmaceutical, health, agriculture, other):				
Organization (specify such as charity/NGO):				

3.	Referring to the prev	vious question, what a	are the most significant l	knowledge sharing activitie	es that you have done?
----	-----------------------	------------------------	----------------------------	-----------------------------	------------------------

4.	What do you consider the most important impacts of this activity? (Examples: requests for additional information or involvement, reported changes in
	behavior/opinions by the audience or by own colleagues, influence on decisions, influence on plans for future related activity, requests for further information, not
	aware of any impact)

BUILDING CAPACITY

5. Please state the number of students (undergraduate, Masters and Doctoral) and Postdoctoral Fellows that were trained or under training as a result of the award/grant. Please enter number of trainees and/or staff that were trained or under training for each row.

Trainees	Number Trained
Undergraduate students	
Masters students	
Doctoral students	
Post professional degree	
Postdoctoral fellows	
Other (please specify):	

6. Please state the number of research and other staff that were recruited/employed and trained as a result of the award/grant.

Please enter number of trainees and/or staff that were trained or under training for each row.

Staff	Number recruited	Number trained
Research assistant		
Research technician		
Other (please specify):		

COLLABORATIONS

7. Please identify the investigators and organizations involved, and a description of the collaboration. Type of collaboration includes funding applications, publication of a paper, implementation of a research project, knowledge translation, etc. Institutions/organizations/companies refer to the PI's collaborators and may come from Manitoba, in Canada or internationally. Presence of formal agreements such as material transfer agreements, memorandums, etc. should be indicated by yes or no [Y/N]. Financial/in-kind contribution refers to that brought into research by collaborators; dollar estimates should be provided. Contributions to the collaboration should be described and distinction made between those by the PI's research team, and by collaborators; these should refer to the financial contributions. Area of impact can be in policy, public services, medical products, cultural, societal, economic or no impact yet.

Type of collaboration	1.	2.	3.	4.
Description of				
collaboration (please				
indicate if multi-disciplinary				
and if so, the disciplines				
involved as well as if the				
collaboration is local,				
national, or international				
Collaborating researchers,				
institutions, organizations,				
and/or companies				
Presence of formal				
agreements [Y/N]				
Start – end date (MM/YYYY				
to MM/YYYY)				
Contribution by				
collaborating				
organization/institution -				
Financial				

collaborating					
organization/institution –					
In-kind					
Contributions by research					
team (non- financial)					
Contributions by					
collaborators (non-					
financial)					
Outputs and outcomes of					
the collaboration					
Area of impact					
9. Why do you consider these the	most significant collaboration	?			
LEVERAGED FUNDING					
		his		of the accord/amount =	
10. Please list any additional fundi refers to research/operating grants		· •			e of funding
refers to research/operating grants	s, renowships, studentships, ilinas	tructure/equipment, traverand	Value of	Start date – End date	Date received
Name of funding agency	Funding program	Type of funding	award/grant (\$)	(MM/YYYY to MM/YYYY)	(MM/YYYY)
At the same time as funding from R	esearch Manitoba				
After the funding from Research Ma	initoba has been completed				
11. If applicable, please describe he	ow the Research Manitoba fun	nding helped to leverage this	fund or support.		

Contribution by

INTELLECTUAL PROPERTY / PRODUCTS

12. Please list all intellectual property (IP) that resulted due to your receiving the Research Manitoba award/grant.

Activity/outcome	Year	Number	Value (\$)	Description	Outcomes/impacts from IP
Patents applied (describe and give number applied)					
Patents approved (number of patents granted/ published)					
Licensing agreements (describe commercial or non- commercial agreements)					
Other, specify					

13. Please list all technical products that were developed as a result of the Research Manitoba award/grant. Technical products can include web tools/application, software, e-business platform, grid application, physical model/kit, new material/compound, new/improved technique/technology, systems, materials and instrumental engineering; detection devices and others. Description should include the type (app, browser add-ons etc.), what it does, the name and other relevant information.

Name of product	Description	License	Open source? [Y/N]	Stage of development	Outcomes/impacts resulting from product

14. Please list all research outputs (e.g., databases and models, tools and methods), that have been developed as a result of the Research Manitoba award/grant. For model of mechanisms or symptoms, indicate if human, mammalian in vivo, in vitro, non-mammalian in vivo as part of the description.

Туре	Description	Provided to other research groups? [Y/N]	Year provided	Outcomes/impacts resulting from database or model
Database/collection of data			p. o	
Data analysis technique				
Computer model/algorithm				
Data handling and control				
Other, specify:				
Biological samples				
Cell line				
Technological assay/reagent				

Model of mechanisms or symptoms		
Physiological assessment or outcome measure		
Improvements to research infrastructure		
Antibody		
Banks/libraries established		
Contributions to banks/ libraries		
Other, specify:		

15. Please list all medical products, interventions and clinical trials that have resulted because of the Research Manitoba award/grant. Type of product can include medical products/interventions, other products, and services/processes. For medical products/ interventions, these can include diagnostic tools, therapeutic interventions, preventive intervention, management of disease and conditions, health and social care services, support tool. For diagnostic tool—indicate if imaging or non-imaging as part of the description. Therapeutic intervention—indicate if drug, vaccine, cellular and gene therapy, medical device, surgery, radiotherapy, psychological/ behavioral, physical or complementary as part of the description. Preventive intervention—indicate if behavioral risk modification, physical/biological risk modification or nutrition and chemoprevention as part of the description. Support tool—indicate if for fundamental research or medical intervention as part of the description. Other products can be consumer products or food products. Consumer products are merchandise that are used daily and purchased for private consumption. Services, processes and standards can refer to consumer products and/or industry. Development status—indicate if initial development; refinement: non-clinical; refinement: clinical, early clinical assessment, late clinical evaluation; market authorization; small scale adoption; or widespread adoption. Year refers to when the development was completed.

Type of products/services	Description	Development status	Tested via clinical trial? [Y/N]	Year (YYYY)	Outcomes/impacts from products/services
Other, specify:					

RESEARCH INFRASTRUCTURE

16. Please state how the award/grant has supported research infrastructure. Research infrastructure are facilities, resources, platforms and related services that are used by the research community to conduct research. These can be physical, digital and biological/chemical (e.g. biobanks), in nature and external to the supported research project.

Name of research infrastructure	Description of research infrastructure	Period used		Period used		# of times used	Description of organization/ company operating research infra	Outcomes/impacts from use of research infrastructure
		Start (YYYY)	End (YYYY)					

INFORMING DECISION MAKING

17. Please explain how the research supported by the award/grant influenced policy, practice, patients, the public, the development of products, services, standards and processes, and the construction of physical and digital infrastructure. Also indicate who the users are/were or who have been using your research results. Please answer all that apply and provide figures when appropriate. Year refers to when the influence on policy or practice was realized. Description should explain how research findings were used and who the users are; in the case of citations, the title(s) of publications, guidelines and/or other documents should be identified. Reach of influence can be local/municipal/provincial, regional, national or international. Sector of influence refers to aerospace, agriculture, social services, policy, education, environment, health care, pharmaceuticals, etc. Impacts refer to improvements in survival, morbidity or quality of life; improved accessibility of public services, improved educational and skill level of workforce, changed public attitudes, economic impacts, etc.

Area of influence	Year	Description (include	Reach of influence	Sector of influence	Outputs/outcomes
		titles of			
		publications)			
Training of practitioners or					
researchers					
Citation in clinical guidelines					
Citation in clinical reviews					
Citation in policy documents					
Citation in in systematic reviews					
Used as evidence in a government					
review					
Used in circulars, briefs, letters					

Participation in committees		
Participation in national consultations		
Contribution to general knowledge		
about the subject		
Changing conventional wisdom		
Role of research in attracting students		
and fellows (indicate number attracted)		
Role of research in attracting		
investigators (indicate number attracted)		
Informing the work of organizations		
Informing/change in theory or		
research methods		
Influence on (health, social, other)		
guidelines (at local, national and/or		
international level)		
Influence on (health, social, other)		
policy (at local, national and/or		
international level)		
Influence on academic, professional,		
and clinical practice (at local national		
and/or international level)		
Influence on existing/new programs		
and/or interventions (at local national		
and/or international level)		
Benefits/information for patients		
Consultations with industry		
Other, specify		

RECOGNITION

18. Please list all prizes, awards or commendations as a result of the Research Manitoba award/grant received from you and/or your research team. Type of award can be a research prize, medal, honorary membership, appointment as editor/adviser, poster/abstract prize, keynote speaker etc.

Type of award	Name of prize/	Name of recipient	Year	Description of award including	Outcomes as a result
	award/commendation		received	reasons and role of recipient	of the commendation

SPIN-OFFS

19. Please provide details about any spin-offs as a result of the Research Manitoba award/grant.

Name of company	Country of operation	Year established	Number employed	Description of company	Outcomes/impacts of company

RESEARCH RESULTS/IMPLEMENTATION

20.	0. Please provide a lay summary of the overall findings and implications according to the original objectives of the research.					
21.	. What are the additional and/or unintended discoveries/achievements/successes? Please be as specific as possible.					

22. To what extent have you achieved the research goals? If the goals have not been met or were partially met, please explain what happened and why. Please be as specific as possible.

Did you accomplish your research goals/objectives?	
Please provide a brief explanation.	
Did you accomplish all the planned activities? Please	
explain causes of changes/delays/non-completion, if any,	
and how these were dealt with.	

23. What steps did you take translate research findings/kno	owledge? Please be as specific as possible.
Describe how stakeholders, end-users, patients and	
others have been involved.	
Describe how findings have been communicated/	
disseminated.	
Provide the status of the KT plan, if any.	
Describe other steps taken to translate research findings.	
24. Please explain any plans in place to help move the reserve	arch forward after the award/grant's conclusion:
How will the findings be used by you or others?	
Will there be changes in direction and scope? Please	
provide a brief explanation.	
What are your plans to seek additional funding after this	
Research Manitoba award/grant? (Please provide an	
outline of next steps including a timeline.)	
25. What lessons did you learn in the development and exe	cution of this research project?
26. How can these lessons be applied in future studies, initi and implementing the research rather than the actual fin	atives or career development? Please present lessons in the context of the process of designing dings.
27. Is there anything else you want to share with Research	Manitoba? Please include any issue or concern.